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CARDIAC HYPERTROPHY
A tail of translational regulation
An RNA-binding protein called PABPC1 has an important role in
determining protein synthesis rates and hypertrophy in the heart.
GILLIAN A GRAY AND NICOLA K GRAY
T
he mammalian heart is a muscular pump
that handles about five litres of blood
per minute in the average human. Muscle
cells known as cardiomyocytes make up 25–35%
of all cells in the heart, with the remainder
largely being vascular endothelial cells and fibro-
blasts (Pinto et al., 2016). The proliferation of
cardiomyocytes is key to the growth of the heart
before birth, and also soon after birth, but most
cardiomyocytes lose their capacity to proliferate
after the early post-natal period in both mice
(Soonpaa et al., 1996) and humans
(Bergmann et al., 2015). Thereafter, cardiac
growth is achieved mainly by increases in the
size of cardiomyocytes in a process known as
hypertrophy.
In adulthood cardiac hypertrophy can occur
as a physiological adaptation to an increased
need to pump blood following sustained athletic
training or during pregnancy (reviewed in
Maillet et al., 2013). Cardiac hypertrophy can
also be pathological in nature – for example,
when it is caused by long-term hypertension.
Although cellular signalling pathways and gene
transcription change in distinct ways during
’physiological’ and ’pathological’ cardiac hyper-
trophy, both require de novo protein synthesis
in order to increase cardiomyocyte size (Fig-
ure 1; reviewed in Heineke and Molkentin,
2006). Now, in eLife, Auinash Kalsotra of the
University of Illinois and co-workers – including
Sandip Chorghade and Joseph Seimetz as joint
first authors – reveal an unexpected role for an
RNA-binding protein called PABPC1 in cardiac
hypertrophy (Chorghade et al., 2017).
PABPC1 (commonly known as PABP1) is one
of the 1000+ RNA-binding proteins found in
humans, and has multiple functions in controlling
the synthesis of new proteins (reviewed in
Smith et al., 2014). However, it is best charac-
terized as a factor that is required for efficient
messenger RNA (mRNA) translation and to
maintain mRNA stability, and it is generally con-
sidered to be an abundant and essential protein
(Smith et al., 2014).
Protein synthesis is surprisingly low in the
adult heart, perhaps reflecting the relatively low
level of cell turnover there. Intriguingly, Chor-
ghade et al. show that PABPC1 is abundant in
the neonatal heart, but is only present at very
low levels in the adult heart, and they go on to
show that the low levels of PABPC1 in the adult
heart are due to reduced translation of PABPC1
mRNA. Chorghade et al. also found that this
reduction in translation coincided with a shorten-
ing of the 3’ poly(A) tail of PABPC1 mRNA: poly
(A) tails are critical for efficient translation but
their length can be exquisitely regulated by a
number of mechanisms (reviewed in
Charlesworth et al., 2013).
Intriguingly, the length of the poly(A) tail of
PABPC1 mRNA and its translation were
increased in experimental models of both physi-
ological hypertrophy (induced by swimming) and
pathological hypertrophy (induced by narrowing
of the aorta to mimic high blood pressure), lead-
ing to an increase in PABPC1 levels.
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Figure 1. The role of the RNA-binding protein PABPC1 in cardiac hypertrophy. In a normal adult heart, cardiomyocytes (CM) show little growth or
turnover, and protein synthesis and PABPC1 levels are low. The temporal overexpression of PABPC1 in adult cardiomyocytes leads to a form of cardiac
hypertrophy (top right) that resembles (green arrow) physiological cardiac hypertrophy (e.g. induced by pregnancy or endurance exercise) but not (red
broken arrow) pathological cardiac hypertrophy (e.g. induced by long-term hypertension). However, a number of features (such as cardiomyocyte
growth, higher protein synthesis and higher levels of PABPC1) are common to both physiological and pathological cardiac hypertrophy. This raises the
question (bottom right) of whether PABPC1 function in other types of cardiac cells (such as endothelial cells or fibroblasts) may be important in the
induction of pathological cardiac hypertrophy. During cardiac hypertrophy, longer poly(A) tails are associated with more efficient translation of the
messenger RNA for PABPC1.
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It was already known that the translation of
PABPC1 mRNA was controlled by two mecha-
nisms (reviewed in Eliseeva et al., 2013), but
uncovering that its poly(A) tail length is also reg-
ulated further underscores how important it is to
control cellular levels of PABPC1. However,
Chorghade et al. found that the 3’untranslated
region of PABPC1 mRNA is not important for its
regulated translation. This is surprising since
studies in multiple cell types have shown that
sequences within the 3’untranslated region nor-
mally regulate poly(A) tail length. Therefore,
more work is needed to clarify the mechanism
by which PABPC1 mRNA translation and poly(A)
tail length is controlled in cardiomyocytes.
The altered levels of PABPC1 suggested that
it may facilitate a dynamic response to an
increased workload being placed on the heart.
Importantly, Chorghade et al. probed the func-
tional relevance of altered PABPC1 levels and in
doing so uncovered new avenues for explora-
tion. Reducing PABPC1 levels in cultured neona-
tal mouse cardiomyocytes blocked the normal
increase in protein synthesis and cell size associ-
ated with stimulus-induced growth: moreover,
this effect that could be rescued with wild-type
PABPC1, but not with mutant PABPC1.
In transgenic mice, the overexpression of
PABPC1 in adult cardiomyocytes increased pro-
tein synthesis and heart size without any loss of
cardiac function, similar to what happens in
physiological hypertrophy (Figure 1). The tran-
scriptional changes that accompanied these
increases were also similar to physiological
rather than pathological hypertrophy. Therefore,
despite the level of PABPC1 increasing in mod-
els of both forms of hypertrophy, increased
PABPC1 levels in cardiomyocytes do not appear
sufficient to drive pathological hypertrophy.
Other types of cardiac cells, including endo-
thelial cells and fibroblasts, proliferate during
pathological hypertrophy and can influence the
behaviour of cardiomyocytes (Figure 1;
Frieler and Mortensen, 2015). Future research
is needed to determine the extent to which
PABPC1 levels in other cardiac cell types may be
involved in this process.
In addition to adding to the growing body of
evidence that translational control has a role in
cardiac hypertrophy, the work of Chorghade
et al. also greatly extends our knowledge of the
physiological roles of PABPC1. Previous whole-
organism studies of PABPC1 function in verte-
brates were confined to the frog X. laevis, where
it is essential for early embryonic development
(Gorgoni et al., 2011).
Since these new results also showed that
PABPC1 levels were highest in fetal and neona-
tal hearts (prior to hypertrophic growth), this
suggests that PABPC1 might have a critical role
in cell proliferation and/or the growth of heart
tissue during heart development and matura-
tion, as well as in adult cardiac hypertrophy.
Thus, ascertaining its function in fetal and neona-
tal hearts in mammals is an exciting question for
the future.
Finally, there is significant interest in invoking
pathways that promote physiological cardiac
hypertrophy as an alternative to the detrimental
structural and functional “remodelling” of the
heart that is associated with heart failure. The
work of Chorghade et al. has opened a new win-
dow on our understanding of cardiac hypertro-
phy, and future research should reveal whether
or not PABPC1 has potential as a therapeutic
target for cardiovascular disease.
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